High blood pressure news and high blood pressure widget

United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmonary arterial hypertension. The NDA will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009.

Blood pressure in low-birth-weight children younger than 3 years of age not only can be measured but should be, researchers at UT Southwestern Medical Center have found.

In America and in other industrialized countries, about 40% of men over age 40 have high blood pressure.

Blood pressure in low-birth-weight children younger than 3 years of age not only can be measured but should be, researchers at UT Southwestern Medical Center have found. The findings appear in the September issue of Pediatrics.